Table 1.
The Syrian Hamster Models in Cancer Immunotherapy.
| Cancer models | Cell lines | Reagents | Immunotherapy approach | Refs |
|---|---|---|---|---|
| Pancreatic cancer | HPD-1NR, HaK |
Oncolytic adenovirus, Vaccinia virus |
Oncolytic virus therapy | (9) |
| HPD1NR, SHPC6, Hap-T1 | Ad-TD-nsIL-12 | Cytokine, Oncolytic virus therapy |
(13) | |
| SHPC6 | VVLΔTK-STCΔN1L-IL21 | Cytokine, Oncolytic virus therapy |
(14) | |
| HPD-1NR | Ad5 | Oncolytic virus therapy | (76) | |
| PGHAM-1 | Dendritic cell (DC) | Therapeutic Cancer Vaccine | (19) | |
| SHPC6 | INGN 007 | Oncolytic virus therapy | (23) | |
| HP-1 | RGD-ΔE3-ADP-ham-IFN | Cytokine, Oncolytic virus therapy |
(25) | |
| HaP-T1 | Ad-OSM, NDV-OSM | Oncolytic virus therapy | (26) | |
| PGHAM-1 | AdCV-hamIFN | Cytokine, Oncolytic virus therapy |
(27) | |
| HapT1 | Ad5-D24, Tumor-infiltrating lymphocytes (TILs) |
Oncolytic virus therapy, Adoptive Cell Therapy | (60) | |
| HaP-T1 | oAd/IL12/GM-RLX αPD-1 |
Cytokine, Oncolytic virus therapy, Immune Checkpoint Inhibitor |
(69) | |
| Hap-T1 | vvdd-tdTomato-hGMCSF | Oncolytic virus therapy, Cytokine | (70) | |
| HapT1 | Ad5/3-E2F-d24-hIL2, rhIL-2, TIL therapy | Cytokine, Oncolytic virus therapy, Adoptive Cell Therapy |
(73) | |
| HapT1 | Ad5/3-E2F-d24-hTNF-α-IRES-hIL-2(TILT-123), Tumor-infiltrating lymphocytes (TILs) |
Cytokine, Oncolytic virus therapy, Adoptive Cell Therapy |
(15) | |
| HPD1NR | Dendritic cell (DC) | Therapeutic Cancer Vaccine | (74) | |
| HaK, PC1 | VRX-007 | Oncolytic virus therapy | (77) | |
| HP-1 | VCN-01 | Oncolytic virus therapy | (78) | |
| HP-1 | VCN-11 | Oncolytic virus therapy | (79) | |
| SHPC6 | VRX-007 | Oncolytic virus therapy | (80) | |
| HaP-T1, HP-1, H2T | Ad-WTLuc | Oncolytic virus therapy | (81) | |
| HaP-T1 | AxE1CAUP | Oncolytic virus therapy | (82) | |
| HaP-T1, H2T | Human adenovirus | Oncolytic virus therapy | (83) | |
| H2T | Ad-DHscIL12 | Cytokine, Oncolytic virus therapy |
(84) | |
| HapT1 | Ad5/3-E2F-d24-vIL2 | Cytokine, Oncolytic virus therapy |
(85) | |
| HapT1, HapT1 AIM2-/- |
Ad5/3-d24-E2F-hTNFa-IRES-hIL2 | Cytokine, Oncolytic virus therapy |
(86) | |
| HaP-T1 | Ad-IL12G Virus-loaded monocytes |
Cytokine, Oncolytic virus therapy |
(87) | |
| Human Esophageal Squamous Cell Carcinoma | SBRC-EC01 | Ad-TD-nsIL12 | Cytokine, Oncolytic virus therapy |
(17) |
| Glioblastoma | HamGSC-1, HamGSC-2 |
Delta-24-RGD | Oncolytic virus therapy | (24) |
| Cheek pouch SCC tumor | HPT11, HPT12 | lp11w/Δ55K | Oncolytic virus therapy | (28) |
| Head and neck cancer | HCPC1 | VVΔTKΔN1L-hIL12 | Cytokine, Oncolytic virus therapy |
(88) |
| Gallbladder cancer | G207 | KIGB-5 | Oncolytic virus therapy | (29, 89) |
| Renal cancer | HaK | KD3-IFN | Cytokine, Oncolytic virus therapy |
(30) |
| HaK | vvdd-tdTomato-hGMCSF | Cytokine, Oncolytic virus therapy |
(70) | |
| HaK | VRX-007 | Oncolytic virus therapy | (80, 90, 91) | |
| HaK | VRX-007, Ad5 | Oncolytic virus therapy | (92) | |
| HaK | INGN 007 | Oncolytic virus therapy | (93) | |
| Lymphosarcoma | TBD 932 | IFN-α | Cytokine | (71, 72) |
| Leiomyosarcoma | DDT1 MF-2 | VRX-007 | Oncolytic virus therapy | (77) |
| DDT1-MF2 | Ad5/3-D24-GMCSF | Cytokine, Oncolytic virus therapy |
(94, 95) |